Outsourcing’s Race Toward Novelty: Recent developments in the outsourcing industry include a focus on early development services, biosimilar production, and RNA technology

Playter, G.

Playter, G..

BioPharm Int. ; 35:42-43, 2022.

Article in English | EMBASE | ID: covidwho-1913177

Keywords

adalimumab; biosimilar agent; insulin glargine; messenger RNA; ranibizumab; SARS-CoV-2 vaccine; article; coronavirus disease 2019; drug approval; drug development; drug industry; drug manufacture; human; race; technology; adalimumab adbm; humira; insulin glargine yfgn; lucentis; ranibizumab nuna

Search on Google

XML

Collection: Databases of international organizations Database: EMBASE Language: English Journal: BioPharm Int. Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

XML

Collection: Databases of international organizations Database: EMBASE Language: English Journal: BioPharm Int. Year: 2022 Document Type: Article